Appointment of Martine Zimmermann as Independent Director to
Inventiva’s Board of Directors
Daix (France), April 19, 2021 –
Inventiva (Euronext Paris and Nasdaq: IVA) is pleased to announce
the appointment of Martine Zimmermann to its Board of Directors as
an independent director. Inventiva’s Board of Directors appointed
Martine Zimmerman to replace Nawal Ouzren, who resigned from the
Board of Directors in order to focus on the growth of Sensorion.
Martine Zimmerman's appointment will be submitted to the
shareholders for ratification at the next general shareholders
meeting.
With over 25 years of
global experience in the pharmaceutical industry, Martine
Zimmermann has been the Senior Vice President and Head of Global
Regulatory Affairs of Alexion Pharma International since June 2016.
Throughout her career, she has acquired extensive expertise as
Regulatory Affairs Executive in both small and large pharmaceutical
groups, holding senior roles in the United States, Europe and
Asia-Pacific. Martine Zimmermann has worked across all phases of
drug development within several therapeutic areas, interacting with
relevant regulatory authorities in key markets, including the U.S.
Food and Drug Administration (FDA), the European Medicines Agency
(EMA) and the Japanese Pharmaceuticals and Medical Devices Agency
(PMDA). She is also an active member of several life-sciences trade
associations and has been a member of the Board of Directors of
U.S.-based Caelum Biosciences since 2019.
Frédéric
Cren, Chairman, CEO and co-founder of
Inventiva, commented: “I am very pleased
to welcome Martine Zimmermann to Inventiva’s Board of Directors.
Her deep knowledge of the industry and her international
experience, paired with her expertise in regulatory matters across
geographies, will be a great addition for the Company. At the same
time, I would like to warmly thank Nawal Ouzren on behalf of the
Board for her valuable contribution to Inventiva over the last two
years and wish her all the best going forward.”
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies
for the treatment of NASH, MPS and other diseases with significant
unmet medical need.
Leveraging its expertise and experience in the
domain of compounds targeting nuclear receptors, transcription
factors and epigenetic modulation, Inventiva is currently advancing
two clinical candidates, as well as a deep pipeline of earlier
stage programs.
Lanifibranor, its lead product candidate, is
being developed for the treatment of patients with NASH, a common
and progressive chronic liver disease for which there are currently
no approved therapies. In 2020, Inventiva announced positive
topline data from its Phase IIb clinical trial evaluating
lanifibranor for the treatment of patients with NASH and obtained
Breakthrough Therapy and Fast Track designation for lanifibranor in
the treatment of NASH.
Inventiva is also developing odiparcil, a second
clinical stage asset, for the treatment of patients with subtypes
of MPS, a group of rare genetic disorders. Inventiva announced
positive topline data from its Phase IIa clinical trial evaluating
odiparcil for the treatment of adult MPS VI patients at the end of
2019 and received FDA Fast Track designation in MPS VI for
odiparcil in October 2020.
In parallel, Inventiva is in the process of
selecting an oncology development candidate for its Hippo
signalling pathway program. Furthermore, the Company has
established a strategic collaboration with AbbVie in the area of
autoimmune diseases. AbbVie has started the clinical development of
ABBV‑157, a drug candidate for the treatment of moderate to severe
psoriasis resulting from its collaboration with Inventiva. This
collaboration enables Inventiva to receive milestone payments upon
the achievement of pre-clinical, clinical, regulatory and
commercial milestones, in addition to royalties on any approved
products resulting from the collaboration.
The Company has a scientific team of
approximately 70 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, as well as in clinical development. It also owns
an extensive library of approximately 240,000 pharmacologically
relevant molecules, approximately 60% of which are proprietary, as
well as a wholly‑owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
InventivaFrédéric CrenChairman &
CEOinfo@inventivapharma.com+33 3 80 44 75 00 |
Brunswick GroupYannick Tetzlaff / Tristan Roquet
Montegon / Aude LepreuxMedia
relationsinventiva@brunswickgroup.com+33 1 53 96 83 83 |
Westwicke,
an ICR CompanyPatricia L. BankInvestor
relationspatti.bank@westwicke.com+1 415 513-1284 |
Important Notice
This press release contains forward-looking
statements, forecasts and estimates with respect to Inventiva’s
clinical trials, clinical trial data releases, clinical development
plans and anticipated future activities of Inventiva. Certain of
these statements, forecasts and estimates can be recognized by the
use of words such as, without limitation, “believes”,
“anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”,
“may”, “will” and “continue” and similar expressions. Such
statements are not historical facts but rather are statements of
future expectations and other forward-looking statements that are
based on management's beliefs. These statements reflect such views
and assumptions prevailing as of the date of the statements and
involve known and unknown risks and uncertainties that could cause
future results, performance or future events to differ materially
from those expressed or implied in such statements. Actual events
are difficult to predict and may depend upon factors that are
beyond Inventiva's control. There can be no guarantees with respect
to pipeline product candidates that the clinical trial results will
be available on their anticipated timeline, that future clinical
trials will be initiated as anticipated, or that candidates will
receive the necessary regulatory approvals. Actual results may turn
out to be materially different from the anticipated future results,
performance or achievements expressed or implied by such
statements, forecasts and estimates, due to a number of factors,
including that Inventiva has incurred significant losses since
inception, Inventiva has a limited operating history and has never
generated any revenue from product sales, Inventiva will require
additional capital to finance its operations, Inventiva's future
success is dependent on the successful clinical development,
regulatory approval and subsequent commercialization of current and
any future product candidates, preclinical studies or earlier
clinical trials are not necessarily predictive of future results
and the results of Inventiva's clinical trials may not support
Inventiva's product candidate claims, Inventiva may encounter
substantial delays in its clinical trials or Inventiva may fail to
demonstrate safety and efficacy to the satisfaction of applicable
regulatory authorities, enrollment and retention of patients in
clinical trials is an expensive and time-consuming process and
could be made more difficult or rendered impossible by multiple
factors outside Inventiva's control, Inventiva's product candidates
may cause undesirable side effects or have other properties that
could delay or prevent their regulatory approval, or limit their
commercial potential, Inventiva faces substantial competition and
Inventiva’s business, preclinical studies and clinical development
programs and timelines, its financial condition and results of
operations could be materially and adversely affected by the
current COVID-19 pandemic and that any new appointments may not be
ratified by the shareholders. Given these risks and uncertainties,
no representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as
of the date of this press release. Readers are cautioned not to
place undue reliance on any of these forward-looking
statements.
Please refer to the Universal Registration
Document for the year ended December 31, 2020 filed with the
Autorité des Marchés Financiers on March 15, 2021, the Annual
Report on Form 20-F for the year ended December 31, 2020 filed with
the Securities and Exchange Commission on March 15, 2021 as well as
the full-year financial report for the year ended December 31, 2020
for additional information in relation to such factors, risks and
uncertainties.
Except as required by law, Inventiva has no
intention and is under no obligation to update or review the
forward-looking statements referred to above. Consequently,
Inventiva accepts no liability for any consequences arising from
the use of any of the above statements.
- Inventiva - PR - Appointment Martine Zimmermann - 19 04 2021 -
EN - VF
Inventiva (EU:IVA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inventiva (EU:IVA)
Historical Stock Chart
From Jul 2023 to Jul 2024